Valneva SE
French vaccine producer
ISIN FR0004056851 LEI 969500DIVIP5VKNW4948
Follow Valneva
Weekly email: filings, results
Revenue, last year
€174.7M
+3% vs prior year
Net income
−€115.2M
−840.6% vs prior year
EPS, diluted
−€0.68
−750% vs prior year
Operating cash flow
−€52.9M
+21.3% vs prior year
Source: ESEF annual reports · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | €174.7M | −€115.2M |
| FY24 | €169.6M | −€12.2M |
| FY23 | €153.7M | −€101.4M |
| FY22 | €361.3M | −€143.3M |
| FY21 | €348.1M | −€73.4M |
| FY20 | €110.3M | −€64.4M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 38.7% | −47% | −66% |
| FY24 | 41.9% | 7.9% | −7.2% |
| FY23 | 34.4% | −53.4% | −66% |
| FY22 | 10.2% | −31.4% | −39.7% |
| FY21 | 46% | −17.6% | −21.1% |
| FY20 | 50.8% | −50% | −58.4% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −€57.3M |
| FY24 | −€81.1M |
| FY23 | −€217M |
| FY22 | −€274.6M |
| FY21 | −€15.3M |
| FY20 | €118.8M |
- Valneva
- Healthcare median
Show the numbers
| Year | Valneva | Healthcare median |
|---|---|---|
| FY25 | −66% | −30.6% |
| FY24 | −7.2% | −47% |
| FY23 | −66% | −58% |
| FY22 | −39.7% | −80.4% |
| FY21 | −21.1% | −71.9% |
| FY20 | −58.4% | −62.2% |